



Statement on the Inclusivity of SARS-CoV-2 Nucleic Acid Testing Card for Variants Detection

The Novel Coronavirus (2019-nCoV) is an RNA virus, which is highly susceptible to mutations. In response to the recent updated multiple variants of the novel coronavirus, Guangzhou Pluslife Biotech Co., Ltd has re-analyzed the alignment results of the detection target regions of the SARS-CoV-2 Nucleic Acid Testing Card. All the results show that our testing card can detect all reported variants accurately and didn't show any false-negative results or off-target situation for the reported variants, which includes but not limited to the novel coronavirus variants such as Alpha (B.1.1.7/Q.7), Beta (B.1.351/B.1.351.2/B.1.351.3), Gamma (P.1/P.1.1/P.1.2), Delta (B.1.617.2/AY.1/AY.2/AY.3/AY.3.1/AY.4/AY.4.2/AY.5/AY.5.1/AY.5.2/AY.6/AY.7/AY.8/AY.9/AY.10/AY.25/AY.27/AY.30/AY.70/AY.74/AY.88/AY.107), the ones have been labeled as "VOC of concern" by the World Health Organization (WHO), Omicron (B.1.1.529/BA.1/BA.1.1/BA.2/BA.2.2/BA.2.75/BA.2.75.2/BA.2.12/BA.2.12.1/BA.3/BA.4/BA.5/BA.5.2/XE/BQ.1.1/**BQ.1/XBB.1.5**) and the WHO VOI-labeled variants Eta (B.1.525), Theta (P.3), Iota (B.1.526), Kappa (B.1.617.1), Lambda (C.37), Mu (B.1.621/B.1.621.1), and the variants Epsilon (B.1.427/B.1.429), Zeta (P.2), XD, XF, etc. We will continue to track and update the latest viral information including mutations and substitutions for SARS-CoV-2 to maintain the specificity and sensitivity of our products.

Guangzhou Pluslife Biotech Co., Ltd

January 5th, 2023

